1	
2	
3	
4	Patterns and functional consequences of antibody speciation in maternal-fetal transfer of coronavirus-
5	specific humoral immunity
6	
7	Andrew P. Hederman ¹ , Hannah M. Brookes ¹ , Harini Natarajan ² , Leo Heyndrickx ³ , Kevin K. Ariën ^{3,4} ,
8	Joshua A. Weiner ¹ , Amihai Rottenstreich ⁵ , Gila Zarbiv ⁶ , Dana Wolf ⁶ , Tessa Goetghebuer ^{7,8} , Arnaud
9	Marchant ⁷ , Margaret E. Ackerman ^{1,2} #
10	
11	
12	¹ Thayer School of Engineering, Dartmouth College, Hanover, NH, USA
13	² Department of Immunology and Microbiology, Geisel School of Medicine at Dartmouth, Dartmouth
14	College, Hanover, NH, USA
15	³ Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
16	⁴ Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
17	⁵ Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical Center
18	⁶ Clinical Virology Unit, Hadassah University Medical Center, Jerusalem, Israel
19	⁷ Institute for Medical Immunology, Université libre de Bruxelles, Charleroi, Belgium
20	⁸ Pediatric Department, CHU St Pierre, Brussels, Belgium
21	
22	
23	#Corresponding Author
24	Margaret E. Ackerman
25	14 Engineering Drive
26	Hanover, NH 03755
27	margaret.e.ackerman@dartmouth.edu
28	(ph) 603 646 9922
29	(fax) 603 646 3856

It is made available under a CC-BY-NC-ND 4.0 International license .

30 Abstract

31 Maternal antibodies serve as a temporary form of inherited immunity, providing humoral 32 protection to vulnerable neonates. Whereas IgG is actively transferred up a concentration gradient via the 33 neonatal Fc Receptor (FcRn), maternal IgA and IgM are typically excluded from fetal circulation. Further, 34 not all IgG molecules exhibit the same transfer efficiency, being influenced by subclass, Fab and Fc 35 domain glycosylation, antigen-specificity, and the temporal dynamics of maternal antibody responses. 36 Here, we investigate the phenotypes and functions of maternal and cord blood antibodies induced by 37 SARS-CoV-2 infection and compare them to those induced by mRNA vaccination, focusing on breadth of 38 antigen recognition and antiviral functions including neutralization and effector function. While cord blood 39 coronavirus-specific antibody functional breadth and potency appeared to be more compromised than 40 binding breadth and potency in both groups, vaccination induced substantially greater function and 41 breadth in cord blood than did natural infection. These functional phenotypes were associated with 42 speciation of the maternal serum repertoires, as some IgG subpopulations were enriched while others 43 were relatively depleted. Relevant to the continued protection of vulnerable populations in the context of a 44 diversifying pathogen, greater breadth was observed for antibody effector functions than for 45 neutralization, and these activities were associated with greater affinity for antigen. This work provides 46 insights into the functional breadth of maternal-fetal antibody responses in the context of novel mRNA 47 vaccines and a recently emerged pathogen that is likely to be a public health burden for the foreseeable

48 future.

It is made available under a CC-BY-NC-ND 4.0 International license .

49 Introduction:

The current COVID-19 pandemic continues to infect and cause severe disease in many 50 51 individuals. While the global death rate has declined, it is estimated that even in a relatively well-52 vaccinated population like the United States, 3,000 deaths per month are attributable to Severe Acute 53 Respiratory Syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for COVID-19¹. The virus' 54 sequence has diverged over time into numerous variants with differing degrees of susceptibility to 55 antibodies induced by exposure to prior variants. Notable variants, including Alpha (B.1.1.7), Beta 56 (B.1.351), Gamma (P.1), Delta (1.617.2), and Omicron (B.1.1.529) have shown the ability, albeit at 57 varying levels, to evade neutralizing antibody responses²⁻¹¹. Across each of these waves of prevalent viral 58 variants, certain populations of individuals remain at greater risk than others for severe COVID-19 59 following infection. Fortunately, while initial vaccine clinical trials did not include pregnant participants, 60 recent data has shown that following vaccination, pregnant women achieve robust antibody responses 61 that are comparable to non-pregnant individuals, while maintaining similar safety profiles, and that vaccination is highly effective in preventing severe disease and death in birthing women¹²⁻²². 62 63 Further, because mammals have evolved to transmit maternal humoral immunity to the 64 fetus/neonate in the form of antibodies transferred across the placenta and via breastmilk, maternal 65 vaccination has the multifaceted goal of not only protecting the mother but also of generating a sufficiently 66 robust antibody response to protect the fetus in utero as well as the neonate during early life²³. Indeed, 67 whether induced by infection or vaccination, the "inheritance" of maternal antibody is a crucial component of neonatal immunity early in life against infectious diseases^{24,25}. While not especially susceptible to 68 69 COVID-19 morbidity and mortality, neonates and children remain at risk of long term post-acute sequelae 70 of COVID-19 (PASC)²⁶. Although rare, these complications can be severe including multisystem 71 inflammatory syndrome in children (MIS-C)²⁷. Additionally, while both maternal infection and maternal 72 vaccination are known to influence maternal and neonatal infection risk, at least for some variants²⁸⁻³⁰, 73 they induce maternal antibody responses with a number of differing attributes, providing an opportunity to 74 evaluate transfer biases and their impacts.

75 Transport of IgG across the placenta is mediated by binding to the neonatal Fc receptor (FcRn) expressed on syncytiotrophoblast cells³¹⁻³⁴. Intriguingly, these antibodies do not bind to FcRn on the cell 76 77 surface, but rather are rescued from degradation following fluid phase uptake, internalization, and 78 acidification of endosomal compartments by a pH-dependent protonation of the Fc domain, which results 79 in increased affinity to FcRn³⁵. As FcRn is then sorted and cycled back to the cell surface, it salvages 80 bound IgG, releasing it at the neutral pH of the extracellular environment. The efficiency of this rescue 81 and transfer across the otherwise highly selective barrier between generations is associated with many 82 factors, including maternal IgG levels over time, IgG subclass and allotype, post-translational 83 modifications on both antigen-binding and Fc domains, and antigen-specificity³⁶⁻⁴³. While some of these 84 factors are thought to drive these differences by directly altering FcRn binding affinity or kinetics, the mechanism(s) whereby other factors relate to transfer phenotypes remains incompletely understood⁴⁴⁻⁴⁶. 85

It is made available under a CC-BY-NC-ND 4.0 International license .

Studies have started to look at the transfer of antibodies following maternal mRNA vaccination against
SARS-CoV-2^{38,47-49}; however, a more thorough analysis of the phenotypes and activity of the transferred
antibodies could provide insight into both protection of neonates from COVID-19 as well as to other
infectious diseases by informing on attributes and activities of maternal immune responses that might
provide for the best defense of vulnerable neonates.
Previous analysis of vaccinated pregnant women has revealed generation of neutralizing SARSCoV-2 specific antibodies as well as antibodies capable of eliciting Fc-mediated effector functions in

mothers⁵⁰⁻⁵². These same antibody attributes are typically present in cord blood at delivery⁵¹. In other
 contexts, however, they are not always present at the levels expected based on antibody titers, indicating

- 95 that while generally well-correlated with maternal serum antibodies at the time of delivery, relative activity
- 96 of antibodies in cord blood are distinct. Studies reporting differences in quantity and quality of transferred
- 97 antibodies have cited numerous factors including maternal antibody levels, FcRn expression level, IgG
- 98 glycosylation, IgG subclass, and antigen-specificity, among others, as potential explanations³⁶⁻⁴³. While it
- 99 is well understood that vaccination- and natural infection-induced antibody responses differ in terms of
- mucosal compartmentalization, induced isotype balances, and epitope-specificities, what remains less
 well studied is the breadth of the antibody functional response in mothers as it compares to matched cord
- 102 blood to SARS-CoV-2 variants of concern (VOC) following these exposures⁵³⁻⁵⁸. These factors are
- 103 important as the virus continues to diversify, population-level uptake of updated and booster vaccinations
- decline⁵⁹, and efforts continue toward a universal vaccine⁶⁰. Overall, understanding the breadth of the
- 105 antibody functional response in vaccinated and convalescent mothers with corresponding matched cord
- 106 blood samples can provide new insights into how neonates may benefit from maternal antibodies, in the
- 107 context of compromised or lost neutralization activity associated with viral variation over time and the
- absence of pathogen-specific IgA and IgM. These insights into the maternal and inherited antibody
- 109 repertoires have implications for how vaccines can be most effectively developed as new variants
- continue to emerge for SARS-CoV-2 as well as for other infectious agents posing risks to neonates andinfants.
- 111 111
- 112 113

114 Results

Distinct antibody responses among cord blood samples from vaccinated and convalescent mothers to SARS-CoV-2 variants

116 *mothers to SARS-CoV-2 variants*

117 To explore antibody profiles to SARS-CoV-2 variants, maternal and matched cord blood serum 118 samples were collected from vaccinated (n=50, Hadassah Medical Center, Israel) and convalescent 119 maternal study participants (n=38, CHU St. Pierre, Belgium) after immunization against or infection by 120 SARS-CoV-2 in the third trimester early in the pandemic (**Supplemental Table 1**). These samples were 121 profiled for antibody magnitude, specificity, and Fc domain characteristics of SARS-CoV-specific IgM, IgA, 122 and IgG across a panel of variants and pertussis and tetanus toxoids as control or comparator

It is made available under a CC-BY-NC-ND 4.0 International license .

123 specificities that are also relevant to neonatal health (Supplemental Table 2). We first explored the 124 antibody binding responses to SARS-CoV-2 Wuhan and VOC in maternal and cord blood as a 125 representation of antibody profiles in neonates born to vaccinated and convalescent mothers. Antibody 126 profiles differed in association with both maternal exposure history and sample type, as shown from the 127 distinct clustering by Uniform Manifold Approximation (UMAP) (Figure 1A). Responses among maternal 128 blood samples clustered closely together, while those in cord samples formed a distinct cluster. Within 129 each of these sample type groups, vaccinated and convalescent subjects formed distinct sub-clusters. 130 Among individual features of the antibody response that were assessed, higher levels of variantspecific IgM but lower levels of variant-specific IgG antibodies were observed in maternal blood from 131 132 convalescent as compared to vaccinated subjects (Figure 1B). Intriguingly, despite the expectation that 133 IgA and IgM would be absent from cord blood samples, some of these responses were nonetheless also 134 elevated in cord blood samples from neonates whose mothers were convalescent (Figure 1B). Given 135 these surprising results, responses measured in each sample were compared with blood samples from 136 naïve subjects across each isotype for SARS-CoV-2 variants and control antigens (Figure 1C). In 137 general, IgM and IgA reactivity toward all of the antigens tested were considerably lower in cord blood 138 than even serum samples from SARS-CoV-2 naïve subjects, consistent with the presence of natural or 139 cross-reactive IgM and IgA antibodies with some ability to bind all of the antigens tested, and the 140 expected lack of IgA and IgM in cord blood. However, levels were not the same in cord blood samples 141 from vaccinated as compared to convalescent dyads for a specific subset of SARS-CoV-2 antigens, 142 including beta, delta, and omicron variants. Elevated IgM and IgA responses to these three antigens in 143 cord blood of convalescent mothers were sufficient to lead to greater activity in both breadth-potency 144 curves (Figure 1D), as well as breadth scores (Figure 1E). Similar elevations were also observed for IgM 145 binding to the receptor binding domain (RBD) for gamma, delta, and omicron and for IgA binding to 146 omicron (Supplemental Figure 1). Neither of the control antigens tested showed this pattern, suggesting 147 that this signal is not the result of transfer of small quantities of these isotypes stemming from maternal 148 infection. An explanation for this phenotype was not readily apparent, though some combination of 149 specific mutations, distinct mutations in specific positions, conformationally-distinct epitopes, post-150 translational modifications, or other factors may contribute to these unique binding profiles. 151 In contrast to IgM and IgA responses, the breadth of IgG responses was elevated in association 152 with vaccination as compared to infection for maternal blood, as previously reported for this cohort. This 153 elevation was also apparent in cord blood (Figure 1D-E). For both exposure histories, IgG binding 154 breadth was comparable between maternal and cord blood (Figure 1C-E). The breadth of RBD-specific 155 IgG also exhibited the same consistency between maternal and cord blood within each group 156 (Supplemental Figure 1), further demonstrating the efficiency of placental transfer even when seroconversion does not occur until during the third trimester. In sum, greater coverage of diverse 157 158 variants is expected in infants whose mothers were immunized rather than infected based on their elevated IgG responses. 159

It is made available under a CC-BY-NC-ND 4.0 International license .

160

161 IgG subclass and FcγR breadth of antibodies in cord blood to SARS-CoV-2 variants differs 162 between vaccination and natural infection

163 Given the stark differences in IgG binding breadth associated with exposure history, we explored the breadth of IgG subclasses and Fcy Receptor (FcyR) binding of spike- (S), RBD-, and control antigen-164 165 specific antibodies in cord blood samples (Figure 2, Supplemental Figures 2-3). IgG1 and IgG3 166 responses exhibited the greatest breadth, followed by IgG2; IgG4 responses were uncommon (Figure 167 2A, left; Supplemental Figure 2). Comparing between exposure histories, while breadth scores for all 168 subclasses were higher following maternal vaccination than infection, this difference was only statistically 169 significant for IgG3 (Figure 2B, top). FcyR binding antibody breadth-potency curves were similar among 170 the receptors tested (Figure 2A, right), and like IgG3, breadth scores were significantly increased in cord blood following maternal vaccination as compared to infection (Figure 2B, bottom). Given the varying 171 172 roles of these subclasses and FcyR to antibody effector functions, these differences may be relevant for 173 the in vivo antiviral activity of cord blood antibodies.

174

175 Biases in the specificity and subclasses of well-transferred IgG

176 We next explored IgG transfer ratios (cord/maternal responses) to evaluate the extent to which 177 antibody sub-populations were differentially transferred to cord blood when mothers were exposed to 178 spike by natural infection or vaccination. Whereas total IgG specific for tetanus and pertussis control 179 antigens was enriched in cord blood (Figure 2C-D), there was less total IgG specific for SARS-CoV-2 S 180 protein present in cord blood than maternal blood for both Wuhan and the most distant VOC, Omicron 181 (Figure 2C). Indeed, for dyads exposed to SARS by either vaccination or natural infection, median levels 182 of total IgG binding to S were decreased in cord as compared to maternal blood (Figure 2D). Among the 183 IgG subclasses, IgG1 was better transferred than IgG2, which was in turn better transferred than IgG3. 184 This pattern or relative differences was consistent across specificities and groups (Figure 2C-D, 185 Supplemental Figure 4). However, the absolute magnitudes differed: transfer efficiency of pertussis and 186 tetanus-specific IgG1, IgG2, and IgG3 was greater than that of SARS-CoV-2-specific subclasses, and 187 transfer efficiency in vaccinated dyads tended to be greater than that observed in convalescent dyads. 188

mRNA vaccination shows increased antibody Fc effector functions and transfer of functional antibodies compared to natural infection

Given these biases in SARS-CoV-2 specific IgG phenotypes between maternal and cord blood
 samples, we next defined the ability of antibodies in cord blood from vaccinated and convalescent dyads
 to elicit Fc-mediated effector functions in *in vitro* assays. For each sample, we measured phagocytosis
 (ADCP), antibody dependent cellular cytotoxicity (ADCC), and complement deposition (ADCD) at three

It is made available under a CC-BY-NC-ND 4.0 International license .

195 serum concentrations (Figure 3A, compared to maternal levels and for RBD in Supplemental Figures 5-

196 6). For cord blood samples from vaccinated dyads, functional activity was well conserved across variants,

197 whereas for the convalescent dyad cord blood samples, there was low activity against the Wuhan strain,

198 and considerable reduction apparent in functional activity to most VOC across all effector functions. In

199 contrast to SARS-CoV-2-specific responses, both vaccinated and convalescent cord blood samples

200 showed robust functional activity to both tetanus and pertussis control antigens across all three functional

201 assays (Figure 3A). Unlike SARS CoV-2-specificities, levels of activity were similar for the control

202 antigens in cord blood drawn after maternal infection as after maternal vaccination.

203 In vaccinated dvads, functional breadth scores were similar between maternal and cord blood 204 samples for both spike (Figure 3A) and RBD antigens (Supplemental Figure 6), suggesting that Fc 205 mediated effector functions induced by vaccination and transferred *in utero* can be quite broad. However, 206 like the IgG binding responses, functional breadth was greater in cord blood from vaccinated than 207 convalescent dyads (Figure 3A, inset). For ADCP, ADCC, and ADCD, vaccinated maternal-cord pairs 208 showed transfer ratios that tended be around one, with slightly higher values for closer VOC, and lower 209 values for more distant VOC (Figure 3B-C, Supplemental Figure 7). Convalescent dyads showed a 210 significantly different profile, with transfer ratios of around one for the Wuhan spike, but a significant 211 reduction in transfer ratio of functional antibodies against VOC. Thus, the decreased magnitude of 212 antibody responses in convalescent mothers is further compounded by decreased transfer efficiency, leaving neonates with considerably lower antibody effector activity against VOC. Again, in contrast to 213 214 observations for SARS-CoV-2 antigens, control antigens typically exhibited functional transfer ratios 215 greater than or equal to one in both groups (Figure 3B-C).

216

217 Effector functions may contribute to protection of neonates in the absence of neutralization

218 Although loss of neutralization has been reported elsewhere for the Omicron variant⁶¹, this loss 219 was confirmed for the participants in this study. Neutralization tests against the Wuhan and Omicron 220 variants were performed for a subset of subjects (Figure 3D). Further, cord blood samples exhibited 221 lower neutralization activity than did maternal blood against the Wuhan strain, consistent with prior 222 reports⁶². Neutralization activity was greater for vaccinated as compared to convalescent dyads, and 223 limited neutralization was observed against the Omicron variant. The transfer efficiency of neutralizing 224 antibodies was poorer than that of antibodies with effector function; it was also lower in convalescent than 225 vaccinated dyads (Figure 3E). Collectively, these results suggest that effector function has the potential 226 to contribute to protection of neonates in cases where neutralization activity is lost or insufficient.

227

228 Antibody functions are differentially mediated by immunoglobulin isotype

229 With prior data showing differences in immunoglobulin (Ig) isotype binding in cord as compared to

230 maternal blood and functional and transfer efficiency differences associated with maternal exposure

It is made available under a CC-BY-NC-ND 4.0 International license .

231 history, we next explored the role each isotype played in eliciting effector functions (Figure 4). Serum 232 from maternal and cord blood was depleted of IgM, IgA, or IgG and tested for each effector function 233 following confirmation of the efficiency (Figure 4A) and specificity (Supplemental Figures 8-9) of 234 depletion. Functional responses for maternal and cord blood samples from vaccinated dyads were 235 completely dependent on IgG, as depleted samples showed a near complete loss of functional activity 236 (Figure 4B-D). In contrast, despite the presence of these additional isotypes, depletion of IgM or IgA from 237 vaccinated dyads had no effect on these effector functions. Maternal and cord blood samples from 238 convalescent dyads also showed dependence on IgG for ADCP and ADCC function (Figure 4B-C), but 239 exhibited a unique profile for ADCD. For the maternal convalescent group, ADCD activity was significantly 240 reduced by IgG depletion, but the magnitude of this reduction was relatively smaller than for other sample 241 types, accounting for only about 10-25% of ADCD activity, the majority of which could instead be attributed to IgM (Figure 4D). Collectively, this data showed that ADCD activity was variably induced by 242 243 IgM or IgG isotypes, depending on antigen exposure history.

244

245 Functional responses to endemic and emergent pathogenic coronaviruses

246 Lastly, induction of immunity beyond SARS-CoV-2 VOC, to other sarbeco- and further CoV 247 families is clinically desirable. The breadth of recognition of SARS-CoV-1 and endemic CoV spike proteins are known to vary in association with SARS-CoV-2 spike exposure history^{63,64}. The differences in 248 249 antibody functional breadth among vaccinated and convalescent dyads across CoV-2 variants led us to 250 explore to what extent this breadth encompasses more distant CoV. We tested binding and effector 251 functions of antibody responses specific for endemic beta CoV HKU1, and OC43, and alpha CoV NL63, 252 and 229E, along with emergent pathogenic SARS-CoV-1 and MERS (Middle Eastern Respiratory 253 Syndrome)-CoV. Among the endemic CoV, which have long circulated in the human population, the beta 254 CoV HKU1 and OC43 are more closely related to SARS-CoV-2 than the alpha CoV NL63 and 229E. 255 providing an opportunity to look at the response to a panel of circulating viruses that differ in their degree 256 of similarity. Likewise, we explored binding and functional responses to SARS-CoV-1 and MERS-CoV to 257 examine what breadth may exist for these viruses to which the dyads evaluated here are presumed 258 naïve.

259 Levels of IgM, IgA, and IgG specific to SARS-CoV-1 but not MERS S protein were elevated in 260 maternal samples from both convalescent and vaccinated dyads as compared to naive subjects (Figure 261 5A). However, different dilutional profiles were observed for these CoV-1 S-specific IgG responses: while 262 infection and vaccination resulted in similar levels of binding antibody detection when serum was tested at 263 a 1:2,500 dilution, when diluted further to 1:5,000, this signal was lost for convalescent subjects while 264 being maintained for vaccinated subjects. As described previously for SARS-CoV-2 antigens, the testing of cord blood samples made clear the detection of low levels of IgM and IgA that react to SARS-CoV-1 265 266 and MERS S in even naïve subjects (Figure 5A). Similarly, IgM and IgA responses to endemic CoV could

It is made available under a CC-BY-NC-ND 4.0 International license .

be detected in maternal blood by virtue of their absence from cord blood (**Figure 5B**). Whereas

vaccination to CoV-2 induced elevated IgG responses to CoV-1 as compared to natural infection when

- 269 diluted serum samples were tested, the opposite pattern was observed for OC43: infection induced a
- 270 greater degree of OC43-specific IgG detected at a 1:5,000 dilution, while similar levels were observed
- when samples were tested at a higher concentration.

Despite the presence of binding antibodies to diverse CoV in both convalescent and vaccinated dyads, antibody effector functions were more limited (**Supplemental Figure 10**). Effector functions were observed in both maternal and cord blood samples of vaccinated but not convalescent dyads for CoV-1 spike (**Figure 5C**), consistent with the binding profiles of dilute serum. These effector functions were present at similar levels in maternal and cord blood, and were lost following IgG depletion (**Supplemental Figure 11**).

Among endemic CoV, vaccinated dyads exhibited only ADCP activity against only stabilized OC43 S2P (**Supplemental Figure 10**), and activity was similar between maternal and cord blood samples. In contrast, convalescent dyads exhibited a diversity of effector functions directed to OC43 S (**Figure 5D**). Consistent with IgG binding across endemic CoV S sub-domains (**Figure 5E**), this activity extended to the OC43 S2 domain (**Figure 5F**), but not to conformationally-stabilized OC43 S2P (**Supplemental Figure 10**). Again, despite the presence of IgM and IgA specific for endemic CoV (**Figure 5B,E**), IgG depletion essentially eliminated all observed activity (**Supplemental Figure 11**).

285 Due to the distinctions in Fc effector functions and the surprisingly differential dilution-286 dependence of IgG binding profiles observed for CoV-1 S and OC43 S2 among vaccinated and 287 convalescent samples, we explored if there may be differences in IgG affinity between these groups using 288 biolayer interferometry (BLI) on a subset of samples. Indeed, whereas the total level of binding IgG 289 antibodies was similar to OC43 S2 for vaccinated and convalescent dyads, affinities were distinct among 290 the groups (Figure 5G-I). Convalescent dyad samples (n=5) showed binding profiles consistent with 291 higher affinity (multiple orders of magnitude) than the vaccinated dyads, exhibiting the slow on- and slow 292 off-rate profile typical of high affinity interactions. Consistent with functional data, these affinities were 293 lower in convalescent cord than in maternal blood, suggesting a possible explanation for the decreased 294 ADCP, ADCC, and ADCD activity observed in cord blood samples. In contrast, IgG from vaccinated 295 dyads exhibited lower magnitudes and the fast on-, fast off-rate profile commonly seen in low affinity 296 interactions. This latter profile was consistent with that observed in naïve individuals, suggesting that 297 infection induces either recall of pre-existing and/or induction of novel cross-reactive antibodies with high 298 affinity, whereas vaccination does not. Using the same method, we explored whether these affinity 299 differences were specific to OC43 S2 by measuring affinities across a panel of antigens (Figure 5 H-I). 300 Across antigens and serum IgG samples, affinities tended to be marginally lower in cord blood than 301 corresponding maternal samples. Greater differences were observed between vaccinated and 302 convalescent IgG samples. The median affinity of vaccine-elicited IgG binding to Wuhan S exceeded that 303 of IgG induced by natural infection. Relative to Wuhan S, affinity to the Omicron variant was reduced in

It is made available under a CC-BY-NC-ND 4.0 International license .

304 both dyad groups, however, the reduction was greater for convalescent than vaccinated dyads (Figure 5 305 H). This pattern held with respect to CoV-1 S as well, against which affinity was further decreased. In 306 contrast to emergent CoV, but like the OC43 S2 domain, affinity for OC43 S was greater in convalescent 307 dyads. Vaccinated dyads demonstrated similar affinities for OC43 as were observed in the SARS-CoV-2 308 naïve subjects. Thus, these affinities corresponded well with effector function profiles: higher effector 309 function and IgG affinity for SARS-CoV-2 antigens were observed in vaccinated dyads, whereas higher 310 effector function and IgG affinity for endemic CoV OC43 antigens were observed in convalescent dyads. 311 These results link effector function to antigen binding affinity as qualitative measures of a polyclonal antibody response that can be distinct from response quantity or magnitude. 312

313

314 Discussion

The distinct antibody responses to SARS-CoV-2 VOC, endemic, and emergent coronavirus 315 316 antigens in maternal and cord blood samples from vaccinated and convalescent dyads captured in this 317 study likely result from an array of contributing factors, including antigen conformations, maternal 318 antibody transfer dynamics, affinity differences, and antigen exposure history, among others. A deeper 319 understanding of these factors in the context of pregnancy has the potential to help inform future 320 development of maternal vaccines targeted to contribute to the protection of neonates, particularly as the 321 virus continues to diverge in response to immune pressure mediated by humoral and cellular immunity in 322 the population. Despite the neutralization resistance of VOC, vaccines remain highly effective in 323 preventing severe disease, suggesting the relevance of multiple potential mechanisms including antibody 324 Fc effector functions.

325 To this end, studying the antibody repertoire of neonates can mimic a passive transfer experiment 326 and has the potential to elucidate some of these mechanisms. Given the persistence and importance of 327 IgG in serum, the selective transfer of maternal IgG makes good biological sense, while the additional 328 passive transfer of maternal IgA present in breastmilk can provide added and more contemporaneous 329 protection at mucosal sites after birth. The evolutionary basis for the preferential transfer of IgGs with certain phenotypes and activities is less clear. Whereas levels of the cytolytic IgG1 subclass in cord blood 330 331 typically exceed maternal blood, IgG3, arguably the most functionally active subclass, is less well 332 transferred. Transfer of IgG2, relatively inert in terms of effector function is typically also lower, while IgG4 333 levels appear to be either low enough or sufficiently variable in transfer efficiency that a global trend is less clear⁶⁵. Additionally, while the importance of FcRn in transfer is clear, these patterns don't precisely 334 335 recapitulate the serum half-life or *in vitro* binding affinities of the IgG subclasses⁶⁶⁻⁶⁸. Further, differences in the efficiency of transfer of antibodies with different pathogen- or antigen-specificities^{24,69}, as well as 336 with variable glycosylation⁷⁰⁻⁷², particularly in the variable region⁷⁰, are also associated with differences in 337 338 transfer efficiency. However, the means by which these attributes may contribute rather than simply 339 correlate with other, mechanistically relevant factors is unclear. The longitudinal profile of maternal

It is made available under a CC-BY-NC-ND 4.0 International license .

responses and total serum IgG levels clearly each play a role⁷³⁻⁷⁵, but samples are typically only tested at
 a snapshot in time, often at delivery, as opposed to characterized with more continuous kinetic profiling.
 Recent work has raised the possibility that additional processes or transporters, including FcγR, may play
 a role^{44,46}.

344 Here, by comparing the SARS-CoV-2 spike-specific antibodies with those that recognize non-345 sarbecovirus antigens, we assessed some of these factors. The generally poorer transfer of total and 346 each individual IgG subclass for SARS-reactive antibodies as compared to antigens that mothers were 347 presumed to be seropositive against before pregnancy suggests the importance of their more recent induction and the contribution of the length of time over which maternal antibodies can be transferred in 348 349 the levels observed in neonates. In contrast, the general consistency between well and poorly transferred 350 subclasses, independent of specificity, points to this factor as generalizable. The relative efficiency of 351 SARS-CoV-2-specific antibody transfer between dyads with a history of vaccination as compared to 352 infection also differed somewhat, with generally improved transfer observed in vaccinated dyads, consistent with a possible influence of inflammation associated with maternal infection. 353

354 Antibody functions were also variably well transferred between exposure history groups. ADCP, 355 ADCC, and ADCD activities against pertussis and tetanus antigens were generally elevated in cord blood, 356 while Wuhan SARS-CoV-2 spike-specific antibody effector functions were typically similar in vaccinated 357 and slightly reduced in convalescent cord as compared to maternal blood. For variants, however, this 358 decrease was dramatic in the context of natural infection, and some activities were essentially 359 undetectable in convalescent cord blood. The reduction in the breadth of antibody function paralleled the 360 reduced breadth of antibody binding and activity observed in natural infection overall, but the magnitude 361 of functional loss suggests that non-linearity, or threshold effects are at play in these activities. As has 362 been reported elsewhere, this pattern was also apparent in neutralization activity, which was greatly 363 reduced in cord blood. As compared to effector functions, broad neutralization activity was relatively 364 sparse, even in maternal blood. Among convalescent participants, even dyads with high Wuhan strain 365 neutralizing titers (>1:200) in maternal serum typically exhibited undetectable activity in cord blood. The 366 poorer neutralization activity of antibodies in cord blood than maternal serum is likely at least partly 367 attributable to the loss of contributions from IgM and IgA. Among other possible contributing factors, this 368 study identified differences in the affinity for antigen as potentially playing a role in defining breadth 369 across effector functions. Vaccination led to higher affinity antibodies against emergent coronaviruses 370 whereas natural infection induced higher affinity antibodies towards endemic coronaviruses. In turn, these 371 affinity profiles were consistent with antibody effector function breadth and potency profiles. Relative to 372 IgG1, the poorer transfer of IgG3, which can exhibit both greater effector function and greater apparent 373 affinity for antigen associated with its greater flexibility and hinge length, may also account for some of the 374 differences observed between maternal and cord blood and between vaccination and infection. Consistent with prior reports⁷⁶, differences were observed in the relative levels of responses and 375 376 effector functions of SARS-CoV-2- and the endemic CoV OC43-specific antibodies that are associated

It is made available under a CC-BY-NC-ND 4.0 International license .

377 with spike stabilization and differences in cross-reactivity of antibodies directed to different sub-domains. 378 However, this study associates these functional distinctions with antibody affinity for antigen, finding that 379 polyclonal IgG pools with higher affinity antibodies exhibit greater effector function. While this study 380 cannot address the relative importance of one antibody function over another, neutralization activity was 381 considerably more limited than binding and effector functions, with less than one in ten dyads exhibiting 382 detectable neutralization of the Omicron strain. Low levels of binding antibodies to other emergent and 383 endemic CoV could be detected, and some were present at levels and with characteristics, such as high 384 affinity, sufficient to induce effector functions. Domain-level mapping of responses directed to endemic CoV implicated the highly conserved S2 domain in these exceptionally broad responses, particularly in 385 386 association with natural infection, and prior work has suggested that they result from cross-reactive 387 clones^{76,77}. As VOC continue to emerge, and antigen-experienced populations benefit from mucosal antibody and T cell responses, the relative importance of serum antibody neutralization titers, which have 388 389 served as a robust correlate of protection in early efficacy trials⁷⁸⁻⁸², may vary. Indeed, the mechanistic 390 relevance of neutralization, at least as typically tested in vitro, has been challenged by observations that non-neutralizing and even antibodies that increase viral infectivity in vitro can provide protection in vivo 391 ^{83,84}. To this end, the broad recognition and function of antibodies raised by vaccination and natural 392 393 infection support the feasibility of "universal" COVID-19 vaccine development efforts.

394 Some limitations this study have already been alluded to. Maternal antibodies were sampled only 395 at the time of delivery, so their dynamic profile is not known. Further, the impact of timing of maternal 396 seropositivity could not be meaningfully evaluated given the relatively narrow window during gestational 397 ages at which exposure occurred. While study participants were enrolled at a similar timepoints in the 398 pandemic, they were drawn from geographically distinct populations. With the exception of neutralization, 399 antibody functions were evaluated in simplified rather than more ideally biologically authentic assays, and 400 cell lines rather than neonatal effector cells were employed to characterize activity in cord blood. 401 Sufficient sample volumes were not available to support evaluation of all specificities and activities in all 402 assays. The mechanisms whereby binding and functional assays show different transfer efficiencies are 403 likely to relate at least in part to differences in IgG subclass transfer, but further study would be needed to 404 more clearly resolve the roles of each antibody attribute to the efficiency of transfer and to each function. 405 Further, evidence of threshold effects was observed in several assays, but it remains unclear whether the 406 thresholds observed in the in vitro assays employed here are consistent those that might exist in vivo. 407 Lastly, while the relevance of antibody binding and effector functions tested in depth here to protection 408 from disease has been suggested in many prior studies⁸⁵, insights into the infection resilience of either 409 mothers or neonates in this study is lacking, and therefore relationships between these measures and 410 disease cannot be addressed here.

Overall, while numerous studies have shown the reduction in neutralization following viral
diversification over time, vaccines remain highly effective at preventing severe disease and death,
pointing to the contributions of other immune mechanisms. This study addresses the passive transfer and

It is made available under a CC-BY-NC-ND 4.0 International license .

- 414 inter-generational inheritance of functionally potent antibodies, and the relative ability of IgG antibodies to
- 415 drive broad recognition and effector activity that may contribute to protection from COVID-19. While
- 416 SARS-CoV-2-specific neutralizing activity was typically lost and antibody binding breadth and effector
- 417 function were typically reduced in cord as compared to maternal blood, effector functions were
- 418 substantially greater and broader following maternal vaccination than infection in both mothers and
- 419 infants. The biases in levels, isotypes, subclasses, affinity for antigen, neutralization and effector function
- 420 breadth and potency that associate with antigen exposure history have implications for protecting diverse
- 421 populations from ever-diversifying viral variants.
- 422

423 Methods

424 Human Subjects

Vaccinated participants (Israel), screened for lack of anti-N SARS-CoV-2 antibody responses, received
 two doses of mRNA-encoded stabilized spike BNT162b2 (n=50) vaccine. Convalescent participants

- 427 (Belgium), had infection status defined by RT-PCR (n=38). While Wuhan was the dominant strain in
- 428 circulation at the time of sample collection, viruses were not typed. Naïve serum was obtained from a
- 429 commercial vendor (BioIVT) prior to approval of vaccines and was screened for anti-N SARS-CoV-2
- 430 antibody responses to exclude donors with previous infection. Characteristics for each study group are
- 431 described in **Supplemental Table 1**. While pregnant subjects completed their vaccination series in the
- 432 third trimester, and most convalescent subjects reported symptoms or tested positive in their third
- 433 trimester, elapsed time since most recent SARS-CoV-2 antigen exposure differed between cohorts, as
- did time to delivery following diagnosis or receipt of the second vaccine dose. Study participants provided
- informed written consent and studies were reviewed and approved by IRBs at individual collection sites
- 436 and Dartmouth.

437 Fc Array

- 438 Antigens were purchased from commercial sources or transiently expressed in Expi293 or HEK293 cells
- and purified via affinity chromatography (**Supplemental Table 2**). Fc receptors were expressed and
- 440 purified as described previously⁸⁶. Antigen-specific antibodies were characterized using the Fc array
- 441 assay^{85,87}. Briefly, antigens were covalently coupled to MagPlex microspheres (Luminex Corporation).
 442 Experimental controls included pooled human polyclonal serum IgG (IVIG), S309 an antibody from a
- 443 SARS-CoV patient that cross-reacts SARS-CoV and SARS-CoV-2, and VRC01, an HIV specific
- 444 antibody^{88,89}. Serum dilutions for profiling varied from 1:250 to 1:5000 depending on detection reagent.
- 445 Unless otherwise noted, concentrations tested were as listed in **Supplemental Table 2**. Antigen-specific
- 446 antibodies were detected by R-phycoerythrin-conjugated secondary reagents specific to human
- immunoglobulin isotypes and subclasses and by Fc receptor tetramers^{90,91}. Median fluorescent intensity
- 448 data was acquired on a FlexMap 3D array reader (Luminex Corporation). Samples were run in technical 449 duplicate.
- 450 Neutralization
- 451 SARS-CoV-2 neutralizing antibodies (nAb) were quantified as previously reported^{85,92} for a subset of 452 maternal and matched cord blood serum samples (23 vaccinated, 26 convalescent, selected based on
- 452 having the highest binding antibody levels from among dyads with sufficient serum volumes available).
- 454 Briefly, serial dilutions of heat-inactivated serum (1/50 to 1/25,600 in EMEM supplemented with 2 mM L-
- 455 glutamine, 100 U/ml-100ug/mL of Pencillin-Streptomycin and 2% fetal bovine serum) were incubated for 1
- 456 hr at 37° C and 7° CO₂ with 3xTCID₁₀₀ of Wuhan strain (2019-nCoV-Italy-INMI1, 008 V-03893) and
- 457 Omicron strain BA.1 (B1.1.529, VLD20211207). A volume of 100 μL of sample-virus mixture was added
- to 100 μL of Vero cells (18,000 cells/well) in a 96 well plate and cultured for five days at 37°C and 7%
- 459 CO₂. Cytopathic effects of viral growth were scored microscopically and the Reed-Muench method was

It is made available under a CC-BY-NC-ND 4.0 International license .

- used to calculate the nAb titer that reduced the number of infected cells by 50% (NT₅₀), which was used
- 461 as a proxy for the nAb concentration in the sample. An internal reference standard composed of a pool of
- serum from naturally infected and vaccinated adults was included in each nAb assay run, which was
- 463 calibrated against the Internationals Standard 21/234 (NIBSC), in accordance with WHO guidance.
- 464 Antibody-Dependent Cellular Phagocytosis (ADCP)
- 465 Characterization of the phagocytic activity of serum antibodies was performed as described
- 466 previously^{85,93}. Briefly, 1 μM yellow-green fluorescent beads (Thermo Fisher, F8813) were covalently
- 467 conjugated to antigen. Beads were then incubated with serum samples for 4 hr with THP-1 cells (ATCC
- 468 TIB-202) at 37°C in 5% CO₂. Afterwards, cells were fixed and analyzed by flow cytometry using a
- 469 MACSQuant Analyzer (Miltenyi Biotec) to define the percentage of cells that phagocytosed one or more
- fluorescent beads and the MFI of this population, the product of which was defined as the phagocytic
- score (arbitrary units). Controls included wells with no added antibody were used to determine the level of
- antibody-independent phagocytosis, S309 and VRC01 antibodies, and concentrated pooled polyclonal
 serum IgG (Sigma Aldrich I4506); samples were tested in three biological replicates.
- 474 Surrogate Reporter Cell Assay of Antibody-Dependent Cellular Cytotoxicity (ADCC)
- 475 A CD16 activation reporter assay system was used as a surrogate for ADCC^{85,94}. First, high binding 96-
- 476 well plates were coated overnight at 4°C with 1 μg/mL of spike or RBD antigen. Following incubation,
- 477 plates were washed (PBS + 0.1% Tween20) and blocked (PBS + 2.5% BSA) at room temperature (RT)
- 478 for 1 hr. Following plate washing, 100,000 CD16- (FcγRIIIa) expressing Jurkat Lucia NFAT (Invivogen,
- jktl-nfat-cd16) cells, cultured according to manufacturer's instructions, and dilute serum samples were
- 480 added to each well in cell culture media lacking antibiotics in a 200 μ L volume. After 24 hrs of culture, 25 481 μ L of supernatant from each well was transferred into a white 96 well plate to which 75 μ L of quantiluc
- 401 μL of supernation from each well was transferred into a white 96 well plate to which 75 μL of quantiluc
 482 substrate was added. After 10 min, luciferase signal was determined by reading plates on a SpectraMax
- 483 plate reader (Molecular Devices). Assay controls included cell stimulation cocktail (Thermo Fischer
- 484 Scientific, 00-4970-93) and ionomycin, buffers alone, spike-specific S309 and HIV-specific VRC01
- 485 monoclonal antibodies, and concentrated pooled polyclonal serum IgG (Sigma Aldrich 14506). Samples
- 486 were run in three biological replicates. In a prior study, this assay correlated well with killing activity
- 487 against a spike-expressing cell line⁸⁵.

488 Antibody-Dependent Complement Deposition (ADCD)

Antibody-dependent complement deposition (ADCD) experiments were performed essentially as 489 previously described^{85,95}. Serum samples were heat inactivated for 30 min at 56°C, prior to incubation for 490 2 hr at RT with assay microspheres. Human complement serum (Sigma, S1764) diluted 1:100 in gel 491 492 veronal buffer (Sigma-Aldrich, GVB++, G6514) was mixed with samples and microspheres at RT with 493 shaking for 1 hr. After washing, samples were incubated with murine anti-C3b (Cedarlane #CL7636AP) at 494 RT for 1 hr followed by staining with anti-mouse IgG1-PE secondary Ab (Southern Biotech #1070-09) at 495 RT for 30 min. A final wash was performed and samples were resuspended into Luminex sheath fluid and 496 MFI acquired on a FlexMap 3D reader. Assay controls included heat-inactivated complement, buffers 497 alone, spike-specific S309 and HIV-specific VRC01 monoclonal antibodies, and concentrated pooled

498 polyclonal serum IgG (Sigma Aldrich 14506). Samples were run in three biological replicates.

499 Antibody depletion

- 500 Antibody depletion experiments were performed on a subset of samples (n=15). Depletions were
- 501 performed using Ig capture select resins following manufacturer's instructions (Thermo Fisher) to deplete
- 502 IgM, IgA, or IgG. Depleted samples along with a mock control were tested in the multiplex assay to
- 503 measure depletion efficiency. Mock depletion samples followed the same protocol as the manufacturer's
- 504 instructions with the exception being that an irrelevant column matrix (Ni-NTA Thermo Fisher) was used. 505

506 Octet Analysis

- 507 Serum was purified for IgG using Melon Gel Purification kit (Thermo Fisher) following the manufacturer's
- 508 instructions. Binding affinities were determined using biolayer interferometry (BLI) on the Forte Bio Octet
- 509 system, essentially as previously described⁹⁶. Antigens were biotinylated with LC-LC no weigh biotin

It is made available under a CC-BY-NC-ND 4.0 International license .

510 (Thermo Fisher, A39257). After 30 min of reaction time, excess biotin was removed with Zeba desalting 511 columns (Thermo Fisher, 89882). To determine binding kinetics, biotinylated antigens were captured on 512 streptavidin Sax-2.0 tips (Forte Bio, 18-5136) and then incubated in dilute IgG. Briefly, biosensors were 513 first equilibrated in PBST (0.05% Tween-PBS) for 180s and activated by dipping into 10 mM glycine (pH 514 1.7) for 20s and PBST 20s for three cycles. Biosensors were then loaded with biotinylated antigen at 515 1mg/ml in PBST for 300s, and dipped into PBST for 300s to reach baseline, prior to a 300s association 516 phase in which they were dipped into IgG, and a 300s dissociation phase in which they were dipped into 517 PBST. Assessments were performed across 3-fold serial dilutions of IgG ranging from 10 mM to 0.013 518 mM. Sample traces of a single concentration (10mM) were plotted for representative results. Tips were 519 regenerated for 20s for each condition in 10mM glycine pH 1.7. Data was aligned and corrected between 520 steps as needed, and signal observed in reference sample wells, comprised of tips loaded with antigen 521 but not dipped into IgG, was subtracted. For kinetic analysis, a 1:1 association and dissociation model 522 was selected in Forte Bio data analysis 7.0 software in order to determine K_D.

- 523
- 524 Data Analysis and Statistical Quantification
- 525 UMAP plots were generated in Python (version 3.11) using the umap-learn package (version0.4).
- 526 Volcano plots were generated in R (version 4.3) using ggplot2. Statistical analysis was performed in
- 527 GraphPad Prism (version 9.7). Statistical test are described in the respective figure legends. Breadth-
- 528 potency curves were defined as the proportion of antigen-specificities exhibiting a signal above a given
- 529 intensity. Curves were generated using the LOWESS curve fit method in Prism for each respective
- subject group. Breadth scores were calculated by taking the geometric mean across antigen specificities
- 531 for each subject. The sample size for each figure includes all subjects from their respective groups unless 532 otherwise noted.
- 533
- 534

535 Acknowledgements

- 536 We would like to thank all participants who enrolled in this study and the study and laboratory staff who
- helped collect and process the samples. A number of antigen expression constructs were provided by
 Dr. Jason McLellan (UT Austin) and the positive control mAb S309 was provided by Dr. Jiwon Lee
- 539 (Dartmouth). The following reagent was produced under HHSN272201400008C and obtained through
- 540 BEI Resources, NIAID, NIH: Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-Related
- 541 Coronavirus 2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from Baculovirus, NR-52307.
- 542 The following reagent was deposited by the Centers for Disease Control and Prevention and obtained
- 543 through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR-52281.
- 544

545 Conflict of Interest

- 546 M.E.A. reports grant support from Be Bio and Moderna unrelated to COVID-19 vaccines.
- 547
- 548 Funding
- 549 This work was supported in part by the National Institute of Allergy and Infectious Diseases
- 550 1U19AI145825, National Cancer Institute P30 CA 023108-41, National Institute of General Medical
- 551 Sciences P20-GM113132. A.M. is Research Director at the F.R.S., FNRS, Belgium.

It is made available under a CC-BY-NC-ND 4.0 International license .

552 **References:**

553	1	Ahmad, F. B., Cisewski, J. A., Xu, J. & Anderson, R. N. COVID-19 Mortality Update - United States,
554		2022. MMWR Morb Mortal Wkly Rep 72 , 493-496 (2023).
555		https://doi.org/10.15585/mmwr.mm7218a4
556	2	Zohar, T. et al. Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality.
557		<i>Cell</i> 183 , 1508-1519.e1512 (2020). <u>https://doi.org/10.1016/j.cell.2020.10.052</u>
558	3	Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2
559		infection. <i>Nat Med</i> 27 , 2032-2040 (2021). <u>https://doi.org/10.1038/s41591-021-01540-1</u>
560	4	Pegu, A. et al. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.
561		Science 373 , 1372-1377 (2021). <u>https://doi.org/10.1126/science.abj4176</u>
562	5	Rees-Spear, C. et al. The effect of spike mutations on SARS-CoV-2 neutralization. Cell Rep 34,
563		108890 (2021). <u>https://doi.org/10.1016/j.celrep.2021.108890</u>
564	6	Schmidt, F. et al. Plasma Neutralization of the SARS-CoV-2 Omicron Variant. N Engl J Med 386,
565		599-601 (2022). <u>https://doi.org/10.1056/NEJMc2119641</u>
566	7	Sievers, B. L. et al. Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced
567		neutralizing activity against Beta and Omicron pseudoviruses. Sci Transl Med 14, eabn7842
568		(2022). <u>https://doi.org/10.1126/scitranslmed.abn7842</u>
569	8	Wang, L. et al. Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies
570		elicited by COVID-19 mRNA vaccines. Nat Commun 13, 4350 (2022).
571		https://doi.org/10.1038/s41467-022-31929-6
572	9	Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130-
573		135 (2021). <u>https://doi.org/10.1038/s41586-021-03398-2</u>
574	10	Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature
575		592, 616-622 (2021). https://doi.org/10.1038/s41586-021-03324-6
576	11	Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-
577		induced sera. Cell 184, 2348-2361.e2346 (2021). <u>https://doi.org/10.1016/j.cell.2021.02.037</u>
578	12	Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 384,
579		403-416 (2021). <u>https://doi.org/10.1056/NEJMoa2035389</u>
580	13	Jackson, L. A. et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med
581		383 , 1920-1931 (2020). <u>https://doi.org/10.1056/NEJMoa2022483</u>
582	14	Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med
583		383 , 2603-2615 (2020). <u>https://doi.org/10.1056/NEJMoa2034577</u>
584	15	Yang, Y. J. et al. Association of Gestational Age at Coronavirus Disease 2019 (COVID-19)
585		Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
586		Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at
587		Delivery. Obstetrics & Gynecology 139, 373-380 (2022).
588		https://doi.org/10.1097/aog.000000000004693
589	16	Fleming-Dutra, K. E. et al. Safety and Effectiveness of Maternal COVID-19 Vaccines Among
590		Pregnant People and Infants. Obstetrics and Gynecology Clinics of North America 50, 279-297
591		(2023). https://doi.org/https://doi.org/10.1016/j.ogc.2023.02.003
592	17	Prasad, S. et al. Systematic review and meta-analysis of the effectiveness and perinatal
593		outcomes of COVID-19 vaccination in pregnancy. <i>Nature Communications</i> 13 , 2414 (2022).
594		https://doi.org/10.1038/s41467-022-30052-w
595	18	Schrag, S. J. et al. Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically
596		Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in
597		the United States. JAMA Netw Open 5, e2233273 (2022).
598		https://doi.org/10.1001/jamanetworkopen.2022.33273

599	19	Piekos, S. N., Price, N. D., Hood, L. & Hadlock, J. J. The impact of maternal SARS-CoV-2 infection
600		and COVID-19 vaccination on maternal-fetal outcomes. <i>Reprod Toxicol</i> 114 , 33-43 (2022).
601		https://doi.org/10.1016/j.reprotox.2022.10.003
602	20	Halasa, N. B. et al. Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants.
603		N Engl J Med 387 , 109-119 (2022). <u>https://doi.org/10.1056/NEJMoa2204399</u>
604	21	Shimabukuro, T. T. et al. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant
605		Persons. N Engl J Med 384, 2273-2282 (2021). https://doi.org/10.1056/NEJMoa2104983
606	22	Zauche, L. H. et al. Receipt of mRNA Covid-19 Vaccines and Risk of Spontaneous Abortion. N Engl
607		J Med 385 , 1533-1535 (2021). <u>https://doi.org/10.1056/NEJMc2113891</u>
608	23	Etti, M. et al. Maternal vaccination: a review of current evidence and recommendations. Am J
609		Obstet Gynecol 226 , 459-474 (2022). <u>https://doi.org/10.1016/j.ajog.2021.10.041</u>
610	24	Palmeira, P., Quinello, C., Silveira-Lessa, A. L., Zago, C. A. & Carneiro-Sampaio, M. IgG placental
611		transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012, 985646 (2012).
612		https://doi.org/10.1155/2012/985646
613	25	Fouda, G. G., Martinez, D. R., Swamy, G. K. & Permar, S. R. The Impact of IgG Transplacental
614		Transfer on Early Life Immunity. ImmunoHorizons 2, 14-25 (2018).
615		https://doi.org/10.4049/immunohorizons.1700057
616	26	Rao, S. et al. Postacute Sequelae of SARS-CoV-2 in Children. Pediatrics 153 (2024).
617		https://doi.org/10.1542/peds.2023-062570
618	27	Feldstein, L. R. et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. New
619		England Journal of Medicine 383 , 334-346 (2020). <u>https://doi.org/doi:10.1056/NEJMoa2021680</u>
620	28	Stock, S. J. et al. SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in
621		Scotland. Nat Med 28, 504-512 (2022). <u>https://doi.org/10.1038/s41591-021-01666-2</u>
622	29	Stock, S. J. et al. Pregnancy outcomes after SARS-CoV-2 infection in periods dominated by delta
623		and omicron variants in Scotland: a population-based cohort study. Lancet Respir Med 10, 1129-
624		1136 (2022). https://doi.org/10.1016/s2213-2600(22)00360-5
625	30	Rahmati, M. et al. Effects of COVID-19 vaccination during pregnancy on SARS-CoV-2 infection
626		and maternal and neonatal outcomes: A systematic review and meta-analysis. Rev Med Virol 33,
627		e2434 (2023). <u>https://doi.org/10.1002/rmv.2434</u>
628	31	Borghi, S. et al. FcRn, but not FcγRs, drives maternal-fetal transplacental transport of human IgG
629		antibodies. Proceedings of the National Academy of Sciences 117 , 12943-12951 (2020).
630		https://doi.org/doi:10.1073/pnas.2004325117
631	32	Vaccaro, C., Bawdon, R., Wanjie, S., Ober, R. J. & Ward, E. S. Divergent activities of an
632		engineered antibody in murine and human systems have implications for therapeutic
633		antibodies. Proc Natl Acad Sci U S A 103, 18709-18714 (2006).
634		https://doi.org/10.1073/pnas.0606304103
635	33	Firan, M. et al. The MHC class I-related receptor, FcRn, plays an essential role in the
636		maternofetal transfer of gamma-globulin in humans. Int Immunol 13 , 993-1002 (2001).
637		https://doi.org/10.1093/intimm/13.8.993
638	34	Ghetie, V. & Ward, E. S. FcRn: the MHC class I-related receptor that is more than an IgG
639		transporter. Immunol Today 18, 592-598 (1997). https://doi.org/10.1016/s0167-5699(97)01172-
640		9
641	35	Burmeister, W. P., Huber, A. H. & Bjorkman, P. J. Crystal structure of the complex of rat neonatal
642		Fc receptor with Fc. <i>Nature</i> 372 , 379-383 (1994). <u>https://doi.org/10.1038/372379a0</u>
643	36	Wang, X. et al. Dynamic changes of acquired maternal SARS-CoV-2 IgG in infants. Sci Rep 11,
644		8021 (2021). https://doi.org/10.1038/s41598-021-87535-x

645	37	Joseph, N. T. <i>et al.</i> Maternal Antibody Response, Neutralizing Potency, and Placental Antibody
646		Transfer After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. <i>Obstet</i>
647		Gynecol 138 , 189-197 (2021). <u>https://doi.org/10.1097/aog.00000000004440</u>
648	38	Atyeo, C. <i>et al.</i> Compromised SARS-CoV-2-specific placental antibody transfer. <i>Cell</i> 184 , 628-
649		642.e610 (2021). <u>https://doi.org/10.1016/j.cell.2020.12.027</u>
650	39	Flannery, D. D. et al. Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2 Antibodies
651		and Placental Transfer Ratios. JAMA Pediatr 175 , 594-600 (2021).
652		https://doi.org/10.1001/jamapediatrics.2021.0038
653	40	Kugelman, N. et al. Maternal and Neonatal SARS-CoV-2 Immunoglobulin G Antibody Levels at
654		Delivery After Receipt of the BNT162b2 Messenger RNA COVID-19 Vaccine During the Second
655		Trimester of Pregnancy. JAMA Pediatr 176, 290-295 (2022).
656		https://doi.org/10.1001/jamapediatrics.2021.5683
657	41	Mithal, L. B., Otero, S., Shanes, E. D., Goldstein, J. A. & Miller, E. S. Cord blood antibodies
658		following maternal coronavirus disease 2019 vaccination during pregnancy. Am J Obstet Gynecol
659		225 , 192-194 (2021). <u>https://doi.org/10.1016/j.ajog.2021.03.035</u>
660	42	Zdanowski, W. & Waśniewski, T. Evaluation of SARS-CoV-2 Spike Protein Antibody Titers in Cord
661		Blood after COVID-19 Vaccination during Pregnancy in Polish Healthcare Workers: Preliminary
662		Results. Vaccines (Basel) 9 (2021). https://doi.org/10.3390/vaccines9060675
663	43	Soysal, A., Bilazer, C., Gönüllü, E., Barın, E. & Çivilibal, M. Cord blood antibody following
664		maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy. Hum
665		Vaccin Immunother 17 , 3484-3486 (2021). https://doi.org/10.1080/21645515.2021.1947099
666	44	Rosenberg, Y. J. <i>et al.</i> Evidence for the Role of a Second Fc-Binding Receptor in Placental IgG
667		Transfer in Nonhuman Primates. <i>mBio</i> 14 , e00341-00323 (2023).
668		https://doi.org/doi:10.1128/mbio.00341-23
669	45	Martinez, D. R., Fouda, G. G., Peng, X., Ackerman, M. E. & Permar, S. R. Noncanonical placental
670		Fc receptors: What is their role in modulating transplacental transfer of maternal IgG? PLoS
671		Pathog 14, e1007161 (2018). https://doi.org/10.1371/journal.ppat.1007161
672	46	Langel, S. N., Otero, C. E., Martinez, D. R. & Permar, S. R. Maternal gatekeepers: How maternal
673		antibody Fc characteristics influence passive transfer and infant protection. <i>PLoS Pathog</i> 16,
674		e1008303 (2020). https://doi.org/10.1371/journal.ppat.1008303
675	47	Flannery, D. D. <i>et al.</i> Comparison of Maternal and Neonatal Antibody Levels After COVID-19
676		Vaccination vs SARS-CoV-2 Infection. JAMA Network Open 5, e2240993-e2240993 (2022).
677		https://doi.org/10.1001/jamanetworkopen.2022.40993
678	48	Rottenstreich, A. <i>et al.</i> Timing of SARS-CoV-2 vaccination during the third trimester of pregnancy
679		and transplacental antibody transfer: a prospective cohort study. <i>Clinical Microbiology and</i>
680		Infection 28 , 419-425 (2022), https://doi.org/https://doi.org/10.1016/i.cmi.2021.10.003
681	49	Beharier. O. <i>et al.</i> Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and
682	-	BNT162b2 mRNA COVID-19 vaccine. The Journal of Clinical Investigation 131 (2021).
683		https://doi.org/10.1172/JCI150319
684	50	Atveo, C. <i>et al.</i> COVID-19 mRNA vaccines drive differential antibody Fc-functional profiles in
685		pregnant, lactating, and nonpregnant women. Sci Transl Med 13 , eabi8631 (2021).
686		https://doi.org/10.1126/scitranslmed.abi8631
687	51	Adhikari, E. H. <i>et al.</i> Diverging Maternal and Cord Antibody Functions From SARS-CoV-2 Infection
688		and Vaccination in Pregnancy. The Journal of Infectious Diseases (2023).
689		https://doi.org/10.1093/infdis/jiad421
690	52	Atyeo, C. G. et al. Maternal immune response and placental antibody transfer after COVID-19
691		vaccination across trimester and platforms. <i>Nature Communications</i> 13 , 3571 (2022).

693	53	Garrett, M. E. et al. Comprehensive characterization of the antibody responses to SARS-CoV-2
694		Spike protein finds additional vaccine-induced epitopes beyond those for mild infection. <i>eLife</i>
695		11 , e73490 (2022). <u>https://doi.org/10.7554/eLife.73490</u>
696	54	Puhach, O. et al. SARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune
697		responses. eBioMedicine 98 (2023). <u>https://doi.org/10.1016/j.ebiom.2023.104893</u>
698	55	Sano, K. et al. SARS-CoV-2 vaccination induces mucosal antibody responses in previously
699		infected individuals. <i>Nat Commun</i> 13 , 5135 (2022). <u>https://doi.org/10.1038/s41467-022-32389-</u>
700		<u>8</u>
701	56	Espino, A. M. et al. The Anti-SARS-CoV-2 IgG1 and IgG3 Antibody Isotypes with Limited
702		Neutralizing Capacity against Omicron Elicited in a Latin Population a Switch toward IgG4 after
703		Multiple Doses with the mRNA Pfizer-BioNTech Vaccine. Viruses 16 (2024).
704		https://doi.org/10.3390/v16020187
705	57	Kiszel, P. <i>et al.</i> Class switch towards spike protein-specific IgG4 antibodies after SARS-CoV-2
706		mRNA vaccination depends on prior infection history. Sci Rep 13, 13166 (2023).
707		https://doi.org/10.1038/s41598-023-40103-x
708	58	Poolchanuan, P. et al. Dynamics of Different Classes and Subclasses of Antibody Responses to
709		Severe Acute Respiratory Syndrome Coronavirus 2 Variants after Coronavirus Disease 2019 and
710		CoronaVac Vaccination in Thailand. <i>mSphere</i> 8, e00465-00422 (2023).
711		https://doi.org/doi:10.1128/msphere.00465-22
712	59	Jacobs, E. T. et al. Understanding low COVID-19 booster uptake among US adults. Vaccine 41,
713		6221-6226 (2023). <u>https://doi.org/10.1016/j.vaccine.2023.08.080</u>
714	60	Zhao, F., Zai, X., Zhang, Z., Xu, J. & Chen, W. Challenges and developments in universal vaccine
715		design against SARS-CoV-2 variants. npj Vaccines 7, 167 (2022). https://doi.org/10.1038/s41541-
716		<u>022-00597-4</u>
717	61	Rössler, A., Riepler, L., Bante, D., Laer, D. v. & Kimpel, J. SARS-CoV-2 Omicron Variant
718		Neutralization in Serum from Vaccinated and Convalescent Persons. New England Journal of
719		Medicine 386 , 698-700 (2022). <u>https://doi.org/doi:10.1056/NEJMc2119236</u>
720	62	Govindaraj, S. et al. COVID-19 vaccine induced poor neutralization titers for SARS-CoV-2 omicron
721		variants in maternal and cord blood. Front Immunol 14, 1211558 (2023).
722		https://doi.org/10.3389/fimmu.2023.1211558
723	63	Lv, H. et al. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.
724		Cell Reports 31 (2020). <u>https://doi.org/10.1016/j.celrep.2020.107725</u>
725	64	Murray, S. M. et al. The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection
726		and vaccine responses. Nature Reviews Immunology 23, 304-316 (2023).
727		https://doi.org/10.1038/s41577-022-00809-x
728	65	Clements, T. et al. Update on Transplacental Transfer of IgG Subclasses: Impact of Maternal and
729		Fetal Factors. Front Immunol 11, 1920 (2020). <u>https://doi.org/10.3389/fimmu.2020.01920</u>
730	66	Mankarious, S. et al. The half-lives of IgG subclasses and specific antibodies in patients with
731		primary immunodeficiency who are receiving intravenously administered immunoglobulin. J Lab
732		<i>Clin Med</i> 112 , 634-640 (1988).
733	67	Irani, V. et al. Molecular properties of human IgG subclasses and their implications for designing
734		therapeutic monoclonal antibodies against infectious diseases. Molecular Immunology 67, 171-
735		182 (2015). https://doi.org/https://doi.org/10.1016/j.molimm.2015.03.255
736	68	Stapleton, N. M. et al. Reduced FcRn-mediated transcytosis of IgG2 due to a missing Glycine in
737		its lower hinge. <i>Sci Rep</i> 9 , 7363 (2019). <u>https://doi.org/10.1038/s41598-019-40731-2</u>
738	69	Dolatshahi, S. et al. Selective transfer of maternal antibodies in preterm and fullterm children.
739		Sci Rep 12, 14937 (2022). https://doi.org/10.1038/s41598-022-18973-4

740	70	Gao, C., Chen, Q., Hao, X. & Wang, Q. Immunomodulation of Antibody Glycosylation through the
741		Placental Transfer. Int J Mol Sci 24 (2023). https://doi.org/10.3390/ijms242316772
742	71	Jennewein, M. F. <i>et al.</i> Fc Glycan-Mediated Regulation of Placental Antibody Transfer. <i>Cell</i> 178 ,
743		202-215.e214 (2019). https://doi.org/https://doi.org/10.1016/j.cell.2019.05.044
744	72	Adhikari, E. H. et al. Diverging Maternal and Cord Antibody Functions From SARS-CoV-2 Infection
745		and Vaccination in Pregnancy. The Journal of Infectious Diseases 229 , 462-472 (2023)
746		https://doi.org/10.1093/infdis/ijad421
747	73	Malek A Sager B & Schneider H Maternal-fetal transport of immunoglobulin G and its
7/8	75	subclasses during the third trimester of human pregnancy. Am I Reprod Immunol 37 , 8-14
740		(1004) https://doi.org/10.1111/i.1600-0807.1004.th00873.x
749	74	(1994). <u>Inteps.//doi.org/10.1111/j.1000-0897.1994.tb00873.x</u> Simister N. E. Discontal transport of immunoglobulin <i>C. Massing</i> 21 , 2265, 2260 (2002)
750	74	Simister, N. E. Placental transport of immunoglobulin G. <i>Vaccine</i> 21 , 3305-3309 (2003).
751		nttps://doi.org/10.1016/s0264-410x(03)00334-7
752	75	Wilcox, C. R., Holder, B. & Jones, C. E. Factors Affecting the FcRn-Mediated Transplacental
753		Transfer of Antibodies and Implications for Vaccination in Pregnancy. Front Immunol 8, 1294
754		(2017). <u>https://doi.org/10.3389/fimmu.2017.01294</u>
755	76	Crowley, A. R. et al. Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-
756		CoV-2 infection but not vaccination with stabilized spike. <i>eLife</i> 11 , e75228 (2022).
757		https://doi.org/10.7554/eLife.75228
758	77	Wang, C. et al. Antigenic structure of the human coronavirus OC43 spike reveals exposed and
759		occluded neutralizing epitopes. Nature Communications 13, 2921 (2022).
760		https://doi.org/10.1038/s41467-022-30658-0
761	78	Goldblatt, D., Alter, G., Crotty, S. & Plotkin, S. A. Correlates of protection against SARS-CoV-2
762		infection and COVID-19 disease. <i>Immunol Rev</i> 310 , 6-26 (2022).
763		https://doi.org/10.1111/imr.13091
764	79	Khoury D.S. et al. Correlates of Protection. Thresholds of Protection, and Immunobridging
765	15	among Persons with SARS-CoV-2 Infection, <i>Emerg Infect Dis</i> 29 381-388 (2023)
766		https://doi.org/10.3201/eid2002.221/22
767	80	Cilbert B B et al A Covid-19 Milestone Attained — A Correlate of Protection for Vaccines New
707	80	England Journal of Modicine 297 , 2202, 2206 (2022)
700		Englunu Journul oj Meulcine 367 , 2203-2200 (2022).
709	01	Inteps.//doi.org/doi.10.1050/NEJMp2211514
//0	81	Garcia-Beitran, W. F. <i>et al.</i> COVID-19-neutralizing antibodies predict disease severity and
//1	~~	survival. Cell 184 , 476-488.e411 (2021). <u>https://doi.org/10.1016/j.cell.2020.12.015</u>
772	82	Salazar, E. <i>et al.</i> Convalescent plasma anti–SARS-CoV-2 spike protein ectodomain and receptor-
773		binding domain IgG correlate with virus neutralization. <i>The Journal of Clinical Investigation</i> 130 ,
774		6728-6738 (2020). <u>https://doi.org/10.1172/JCI141206</u>
775	83	Pierre, C. N. et al. Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice
776		against severe disease using Fc-mediated effector functions. PLoS Pathog 20, e1011569 (2024).
777		https://doi.org/10.1371/journal.ppat.1011569
778	84	Li, D. et al. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing
779		antibodies. Cell 184, 4203-4219.e4232 (2021). <u>https://doi.org/10.1016/j.cell.2021.06.021</u>
780	85	Hederman, A. P. et al. SARS-CoV-2 vaccination elicits broad and potent antibody effector
781		functions to variants of concern in vulnerable populations. <i>Nature Communications</i> 14, 5171
782		(2023). https://doi.org/10.1038/s41467-023-40960-0
783	86	Boesch, A. W. <i>et al.</i> Highly parallel characterization of IgG Fc binding interactions. <i>MAbs</i> 6. 915-
784		927 (2014), https://doi.org/10.4161/mabs.28808
785	87	Brown, E. P. <i>et al.</i> High-throughput, multiplexed IgG subclassing of antigen-specific antibodies
786	5.	from clinical samples. <i>Limmunol Methods</i> 386 , 117-123 (2012)
787		https://doi.org/10.1016/i.jim 2012.09.007
, , ,		https://doi.org/10.1010/J.jim.2012.03.007

788	88	Pinto, D. <i>et al.</i> Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
789		Nature 583 , 290-295 (2020). <u>https://doi.org/10.1038/s41586-020-2349-y</u>
790	89	Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal
791		antibodies to HIV-1. Science 329 , 856-861 (2010). <u>https://doi.org/10.1126/science.1187659</u>
792	90	Brown, E. P. et al. Multiplexed Fc array for evaluation of antigen-specific antibody effector
793		profiles. J Immunol Methods 443, 33-44 (2017). <u>https://doi.org/10.1016/j.jim.2017.01.010</u>
794	91	Brown, E. P. et al. Optimization and qualification of an Fc Array assay for assessments of
795		antibodies against HIV-1/SIV. J Immunol Methods 455, 24-33 (2018).
796		https://doi.org/10.1016/j.jim.2018.01.013
797	92	Arien, K. K. et al. Three doses of BNT162b2 vaccine confer neutralising antibody capacity against
798		the SARS-CoV-2 Omicron variant. NPJ Vaccines 7, 35 (2022). <u>https://doi.org/10.1038/s41541-</u>
799		<u>022-00459-z</u>
800	93	Ackerman, M. E. et al. A robust, high-throughput assay to determine the phagocytic activity of
801		clinical antibody samples. J Immunol Methods 366, 8-19 (2011).
802		https://doi.org/10.1016/j.jim.2010.12.016
803	94	Butler, S. E. et al. Distinct Features and Functions of Systemic and Mucosal Humoral Immunity
804		Among SARS-CoV-2 Convalescent Individuals. Frontiers in Immunology 11 (2021).
805		https://doi.org/10.3389/fimmu.2020.618685
806	95	Fischinger, S. et al. A high-throughput, bead-based, antigen-specific assay to assess the ability of
807		antibodies to induce complement activation. J Immunol Methods 473, 112630 (2019).
808		https://doi.org/10.1016/j.jim.2019.07.002
809	96	Tolbert, W. D. et al. Decoding human-macaque interspecies differences in Fc-effector functions:
810		The structural basis for CD16-dependent effector function in Rhesus macaques. Front Immunol
811		13 , 960411 (2022). <u>https://doi.org/10.3389/fimmu.2022.960411</u>
812		

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 1: Antibody isotype, magnitude, and breadth across SARS-CoV-2 VOC in maternal and cord blood samples following vaccination or natural infection. A. Coronavirus-specific antibody response features after dimensional reduction in maternal (filled) and cord (open) samples among convalescent (n = 38) (blue) or vaccinated (n = 50) (green) individuals. B. Volcano plot presenting the fold-change (x-axis) and statistical significance (Mann Whitney test, y-axis) of differences between convalescent and vaccinated participants. Antibody isotype is indicated by shape, with RBD and whole spike indicated in hollow and filled symbols, respectively. SARS-CoV-2 variant is indicated by color. C. Median Fluorescent Intensity (MFI) of IgG responses to spike of SARS CoV-2 VOCs as defined by multiplex assay for IgM (top), IgA (middle), and IgG (bottom). Responses among SARS-CoV-2 naïve subjects (n = 38) are shown in black. Bar indicates the median response. D. Breadth-potency curves represent the fraction of subjects with a response exceeding a given level for IgG antibody responses across the panel of VOC. Population means are shown with a thick line, and individual subjects illustrated in thin lines. E. IgG breadth scores for each subject. Bar indicates the median. Statistical significance was defined by ANOVA Kruskal–Wallis test with Dunn's correction and α =0.05 (*p<0.05, **p<0.01, ***p<0.001, ***p<0.001).







Figure 3: mRNA vaccination results in superior breadth of SARS-CoV-2- specific Ab effector function and neutralization in cord blood. A. Ab effector functions in cord blood from vaccinated (top, green shading) and convalescent (bottom, blue shading) cord blood for SARS spike variants or pertussis and tetanus control (red box) antigens. Phagocytosis, ADCC, and Complement deposition activities were assessed at each of three serum dilutions (1:50, 1:100, 1:250). Functional activity is reported in arbitrary units (AU), relative light units (RLU), and median fluorescent intensity (MFI). Inset. Functional breadth scores across variants in maternal, cord, and naïve subject samples. Statistical significance was defined by ANOVA Kruskal–Wallis test with Dunn's correction and $\alpha = 0.05$. B-C. Transfer ratios (cord/maternal) of Fc effector functions to indicated antigens in vaccinated (green) or convalescent (blue) dyads at the 1:50 dilution for individual antigens (B) and for the set of SARS and control antigens (C). D. Neutralization titers (NT₅₀) observed for a subset of vaccinated (n=23) (green) and convalescent (n=26) (blue) maternal and cord samples against Wuhan (black) and Omicron (orange) strains. The limit of detection (LOD) is indicated by the horizontal dotted line. E. Transfer ratios of neutralization activity. Bars indicates median. Unless otherwise noted, data presented includes samples from 37 naive subjects, and 50 vaccinated at 88 convalescent dyads.



Figure 4: Contributions of each isotype to antibody effector functions in cord and maternal blood. Maternal (M) and cord (C) blood samples from vaccinated (green, n=15) and convalescent (n=15) dyads depleted of IgM (top), IgA (center), and IgG (bottom) antibodies. **A-D.** Binding levels (**A**, left) and effector functions (**B-D**) (right) to Wuhan spike protein were measured on mock and depleted (+) samples for each isotype to measure efficiency of each depletion and the impact on antibody activity against Wuhan spike antigen. Mock and depleted (+) samples were compared using a paired mixed effect model corrected for multiple hypothesis testing using the Benjamini, Krieger, and Yekutieli to control the false discovery rate (*q<Q, where Q=0.05). Functional activity is reported in arbitrary units (AU), relative light units (RLU), and median fluorescent intensity (MFI).

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 5. Cross reactivity to emergent and endemic coronavirus. A. Coronavirus-specific antibody response features after dimensional reduction in maternal (filled) and cord (open) samples among convalescent (n = 38) (blue) or vaccinated (n = 50) (green) individuals. Naive subjects (n=37) are shown in black. IgG binding experiments were performed at 1:2500 and 1:5000 dilutions. IgM, IgA, and IgG binding responses to SARS-CoV-1 S and MERS S. B. IgM, IgA, and IgG binding responses to endemic coronaviruses HKU1, OC43, NL63, and 229E. All antigens are full length spike. C. ADCP, ADCC, and ADCD functional responses to SARS-CoV-1 spike. D. ADCP, ADCC, and ADCD responses against OC43 S. E. IgM, IgA, and IgG antibody binding profiles to endemic coronavirus antigens in other conformations (HKU1 S1, OC43S2, OC43S2P, NL62 S1, 229E S1). F. ADCP, ADCC, and ADCD responses against OC43 S2 antigen. Functional activity is reported in arbitrary units (AU), relative light units (RLU), and median fluorescent intensity (MFI). G. Antibody association and dissociation traces for affinity analysis of binding to OC43 S2 for a subset of samples from each group (n=5) at 10 mM. H. Binding of each subject to the panel of antigens measured. I. Heatmap antibody affinities (K_D M) to each antigen tested. Darker red denotes higher affinity binding interaction.